Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $70.44 USD
Change Today -1.32 / -1.84%
Volume 3.3M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals Earns $15 Million from GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. announced that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx. The Phase 2/3 study of ISIS-TTRRx is a randomized, double-blind, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with FAP. The fifteen month study will measure the effects of ISIS-TTRRx on neurological dysfunction and on quality-of-life.

Isis Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Isis Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $84,861,000 compared with $42,248,000 for the same period a year ago. Profit from operations was $10,080,000 compared with loss from operations of $19,858,000 for the same period a year ago. Income before income tax was $15,644,000 compared with loss before income tax of $23,752,000 for the same period a year ago. Net income was $31,053,000 or $0.25 per diluted share compared with net loss of $24,276,000 or $0.21 per diluted share for the same period a year ago. Pro forma income from operations was $18,568,000 compared with pro forma loss from operations of $16,757,000 for the same period a year ago. Pro forma net income was $39,541,000 compared with pro forma net loss of $21,175,000 for the same period a year ago. The company revenue fluctuates based on the nature and timing of payments under agreements with its partners, including license fees, milestone-related payments and other payments. For the full year, the company reported total revenues of $214,161,000 compared with $147,285,000 for the same period a year ago. Loss from operations was $47,730,000 compared with $51,666,000 for the same period a year ago. Loss before income tax was $54,391,000 compared with $66,558,000 for the same period a year ago. Net loss was $38,984,000 or $0.33 per basic and diluted share compared with $60,644,000 or $0.55 per basic and diluted share for the same period a year ago. Pro forma loss from operations was $16,347,000 compared with $40,248,000 for the same period a year ago. Pro forma net loss was $7,601,000 compared with $49,226,000 for the same period a year ago. The company’s net loss for the year ended December 31, 2014 decreased significantly compared to 2013 primarily due to a decrease in company’s net operating loss, the gain from its investment in Regulus, and the tax benefit the company recorded in 2014 offset, in part, by the non-cash loss on company’s early retirement of a large portion of its 2 % Notes. For 2015, the company projects a pro forma net operating loss in the mid $50 million range, which is very similar to 2014 guidance.

Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

Isis Pharmaceuticals, Inc. announced positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE). HAE is a severe and rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE affects approximately 20,000 patients in the United States and Europe and can be fatal if swelling occurs in the airway. The Phase 1 study of ISIS-PKKRx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-PKKRx. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After only 3 weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33%, 69%, 87% and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.

Isis Pharmaceuticals, Inc., 2014 Earnings Call, Feb 27, 2015

Isis Pharmaceuticals, Inc., 2014 Earnings Call, Feb 27, 2015

Isis Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Isis Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $70.44 USD -1.32

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $38.94 USD -0.32
Acorda Therapeutics Inc $34.74 USD -0.56
Depomed Inc $23.44 USD -0.77
Regulus Therapeutics Inc $20.70 USD -0.43
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.6x
Price/Book 32.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.